Clinical Trials in Detroit

Showing 10461-10480 of 19,719 trials

Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

NCT04574596

This is a prospective, observational, multicenter, case-control study.

Duke University300 participantsStarted Nov 2020

Torrance, California, United States • Aurora, Colorado, United States • Atlanta, Georgia, United States +10 more locations

WITHDRAWN< 1 mile

Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19

NCT04403035

This study is a comparison of the ID Now COVID-19 (Abbott) assay to the Accula SARS-CoV-2 (Mesa Biotech) assay to assist in the identification of infection with COVID-19. The tests will be compared for sensitivity, specificity, positive predictive value and negative predictive value.

Covid-19

Henry Ford Health SystemStarted May 2020

Detroit, Michigan, United States

COMPLETEDPhase 2< 1 mile

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

NCT00171223

During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study provided that, in the opinion of the investigator, they had benefited from treatment with STI571 and there were no safety concerns.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Novartis Pharmaceuticals532 participantsStarted Dec 1999

Los Angeles, California, United States • Tampa, Florida, United States • Chicago, Illinois, United States +25 more locations

Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

Find Trials by Condition in Detroit

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Scoring System for Inhalation Injury

Prospective US Radiofrequency SUI Trial

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Serum Concentrations of Pregnancy-associated Proteins for Assessment of Gestational Age Before Abortion

Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia

Alcohol and Implicit Process in Sexual Risk Behavior in MSM

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia